What Makes a Kinase Promiscuous for Inhibitors?
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Summary: ATP-competitive kinase inhibitors often bind several kinases due to the high conservation of the ATP binding pocket. Through clustering analysis of a large kinome profiling dataset we found a cluster of eight promiscuous kinases that on average bind more than five times more kinase inhibitors than the other 398 kinases in the dataset. To understand the structural basis of promiscuous inhibitor binding, we determined the co-crystal structure of the receptor tyrosine kinase DDR1 with the type I inhibitors dasatinib and VX-680. Surprisingly, we find that DDR1 binds these type I inhibitors in an inactive conformation typically reserved for type II inhibitors. Our computational and biochemical studies show that DDR1 is unusually stable in this inactive conformation, giving a mechanistic explanation for inhibitor promiscuity. This phenotypic clustering analysis provides a strategy to obtain functional insights not available by sequence comparison alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“In addition, the D681N/Y/G mutations in PDGFRA (Asp671 of the salt bridge in DDR1) are activating mutations that confer resistance to imatinib and sunitinib (COSMIC Study: COSU419, COSU375) (Zehir et al., 2017).”
OpenMM 7: Rapid development of high performance algorithms for molecular dynamics
Eastman, P., Swails, J., Chodera, J. D., McGibbon, R. T., Zhao, Y., Beauchamp, K. A., Wang, L.-P., Simmonett, A. C., Harrigan, M. P., Stern, C. D., et al. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005659 · Cited by 2,748 · cited 1×
“, 2004) followed by 100 ps explicit solvent simulation under isothermal-isobaric (NPT) conditions) (Eastman et al., 2017; Shirts and Pande, 2000; Eastman et al., 2013).”
Self-citationOnufriev, A., Bashford, D., & Case, D. A. (2004) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20033 · Cited by 2,507 · cited 1×
“18) on Folding@home after a short equilibration period (consisting of 100 ps implicit solvent simulation using the OBC GBSA implicit solvent model (Onufriev et al., 2004) followed by 100 ps explicit solvent simulation under isothermal-isobaric (NPT) conditions) (Eastman et al.”
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Markov models of molecular kinetics: Generation and validation
Prinz, J.-H., Wu, H., Sarich, M., Keller, B., Senne, M., Held, M., Chodera, J. D., Schütte, C., & Noé, F. (2011) · The Journal of Chemical Physics · doi:10.1063/1.3565032 · Cited by 1,275 · cited 1×
“Markov state models (MSM) (Prinz et al., 2011) were then built for all the mutant variants within the TICA space of the WT-protonated simulations.”
Self-citationIdentification of slow molecular order parameters for Markov model construction
Pérez-Hernández, G., Paul, F., Giorgino, T., De Fabritiis, G., & Noé, F. (2013) · The Journal of Chemical Physics · doi:10.1063/1.4811489 · Cited by 990 · cited 1×
“The time-lagged independent component analysis (TICA) projection was then calculated from these coordinates to find the most kinetically relevant linear combination (Perez-Hernandez et al., 2013), and cumulative sum of the eigenvalues began to flatten despite the small number coordinates used (Figure S4A).”
The target landscape of clinical kinase drugs
Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science · doi:10.1126/science.aan4368 · Cited by 854 · cited 1×
“Phenotypic Clustering Identifies a Group of Unusually Promiscuous Kinases Several screens of kinase inhibitor collections against large panels of kinases have been conducted in an effort to characterize the selectivity of kinase inhibitors and to determine which fraction of the kinome can be inhibited with existing in…”
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
Wu, P., Nielsen, T. E., & Clausen, M. H. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.008 · Cited by 457 · cited 1×
“Because many diseases are associated with aberrant protein kinase activity, targeted kinase inhibitors are clinically highly successful, such as imatinib in cancer therapy (Druker et al., 2006; Fabbro, 2015; Wu et al., 2016).”
Cited by
Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
Scalable emulation of protein equilibrium ensembles with generative deep learning
Lewis, S., Hempel, T., Jiménez-Luna, J., Gastegger, M., Xie, Y., Foong, A. Y. K., Satorras, V. G., Abdin, O., Veeling, B. S., Zaporozhets, I., et al. (2025) · Science · doi:10.1126/science.adv9817 · Cited by 390
Brown, B. P., Stein, R. A., Meiler, J., & Mchaourab, H. S. (2024) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c01081 · Cited by 41
Empowering AlphaFold2 for protein conformation selective drug discovery with AlphaFold2-RAVE
Gu, X., Aranganathan, A., & Tiwary, P. (2024) · eLife · doi:10.7554/elife.99702.3 · Cited by 33
(2024) · doi:10.1038/s41467-024-52146-3 · Cited by 32
Metadata
- Authors
- Hanson, S. M., Georghiou, G., Thakur, M. K., Miller, W. T., Rest, J. S., Chodera, J. D., & Seeliger, M. A.
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 26
- Issue
- 3
- Pages
- 390-399.e5
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- OpenAlex
- W2908488634
- Cited by
- 103
- References
- 9
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: What Makes a Kinase Promiscuous for Inhibitors? https://app.cochat.ai/papers/10.1016/j.chembiol.2018.11.005
- The paper
- Hanson, S. M., Georghiou, G., Thakur, M. K., Miller, W. T., Rest, J. S., Chodera, J. D., & Seeliger, M. A. (2019). What Makes a Kinase Promiscuous for Inhibitors? Cell Chemical Biology. https://doi.org/10.1016/j.chembiol.2018.11.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.